Clinical Trial Update: Nivolumab and BO-112 Before Surgery for the Treatment of Resectable Soft Tissue Sarcoma [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating nivolumab plus BO-112 as a neoadjuvant treatment before surgery for resectable soft tissue sarcoma, including multiple sarcoma subtypes…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Leiomyosarcoma
• Malignant Peripheral Nerve Sheath Tumor
• Myxofibrosarcoma
• Pleomorphic Rhabdomyosarcoma
• Retroperitoneal Sarcoma
• Soft Tissue Sarcoma
• Synovial Sarcoma
• Undifferentiated Pleomorphic Sarcoma

Drugs mentioned

• BO-112 (BO-112)
• nivolumab (nivolumab)

Snippet

Sponsor: Jonsson Comprehensive Cancer Center | Conditions: Leiomyosarcoma, Malignant Peripheral Nerve Sheath Tumor | Phase 1 | Status: ACTIVE_NOT_RECRUITING